The prefilled syringes market size in the Asia-Pacific was valued at USD 800 million in 2024. The market size in Asia-Pacific is expected to experience a CAGR of 7.95% from 2025 to 2033 and be worth USD 1,593 million by 2033 from USD 864 million in 2025.
The Asia-Pacific region is presently dominating the global prefilled syringe market due to rising chronic diseases and the increasing aged population. The prefilled syringes market in the Asia Pacific is rising due to the advanced development of in-home healthcare and the benefits of using a traditional prefilled syringe globally. The growing usage of injectable dosage forms is further promoting the growth rate of the Asia-Pacific market. Also, increasing demand for self-administrated and self-injection for higher bioavailability is driving the prefilled syringe market. In addition, the rising aged population and an increasing number of people with diabetes are fuelling the market growth.
However, several new drug delivery methods have come up in the market, and stringent government regulations hamper the market's growth.
The Asia Pacific is one of the most revenue-generating markets for prefilled syringes worldwide. The main reason for the highest growth rate exhibited by Asia-Pacific in the forecast is that this market is at a nascent stage and is ripe for investment with a massive potential for growth. Japan accounts for the majority share both in terms of volume and revenue.
India is one of the most lucrative regional markets in the Asia-Pacific region and is predicted to do well during the forecast period. India has many medical device manufacturing companies that import material, which is almost 75 % of total sales. In that, 60 % of the market is occupied by syringes. In 2022, Dr. Reddy introduced a new single-dose prefilled syringe after US Food and Drug Administration approval.
China had the most significant share in the Asia-Pacific market in 2024 and is estimated to register a healthy CAGR during the forecast period. According to WHO, the number of Type 2 diabetes patients in China has doubled in the last two decades, and currently, 110 million people have diabetes in China, according to WHO. US Food and Drug Administration approved Enbrel prefilled syringe in China to treat spondylitis.
Japan is expected to account for a substantial share of the Asia-Pacific market during the forecast period. An increasing aged population in Japan and growing demand for double chamber prefilled syringes in the market are leveling up the growth of the prefilled syringe market. The Parenteral Drug Association (PDA) Japan has initiated syringe self-administration to help biopharma and biotech companies with clinical trials and their basic needs, driving the Japanese prefilled syringe market.
South Africa is considered one of the hotspots in the APAC region and is forecasted to register a healthy CAGR over the forecast period. The development in the healthcare sector and growing demand for advanced prefilled syringes are driving the South Korean prefilled syringe market. SK Bioscience launched a new advanced Shingles vaccine in a prefilled syringe that provides water for injection to reduce the steps of the conventional vial formulation.
A few prominent companies operating in the APAC Prefilled Syringes Market profiled in this report are Becton Dickinson and Company, Gerresheimer AG, SCHOTT AG, West Pharmaceutical Services, Ompi, Catalent, Inc., Weigao Group, Vetter Pharma International GmbH, Nipro Corporation & MedPro Inc.
This research report on the Asia-Pacific prefilled syringes market has been segmented and sub-segmented into the following categories:
By Material
By Type
By Design
By Application
By Distribution Channel
By Country
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region